Skip to main content

Werewolf Therapeutics, Inc.

HOWL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001785530

In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Werewolf Therapeutics, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of HOWL: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders3938−1
Shares20.9M24.0M+3.10M (+14.8%)
Value$42.8M$62.5M+$19.6M (+45.8%)

New holders (7)

Institutions that held Werewolf Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to HOWL in Q1 2023
InstitutionSharesValue% of portfolio
Marshall Wace, LLP120,936$314.4K0.00%
Schonfeld Strategic Advisors LLC73,418$190.9K0.00%
Edgewood Management LLC50,000$130.0K0.00%
Man Group plc–$117.3K0.00%
HBK Sorce Advisory LLC26,454$68.8K0.00%
Bailard, Inc.18,127$47.1K0.00%
FMR LLC2,100$5.46K0.00%

Sold out (8)

Institutions that held Werewolf Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of HOWL in Q1 2023
InstitutionShares, Q4 2022Value, Q4 2022
Oasis Management Co Ltd.246,305$504.9K
Tejara Capital Ltd128,800$264.0K
Jacobs Levy Equity Management, Inc101,221$207.5K
Ergoteles LLC26,501$54.3K
Jane Street Group, LLC22,064$45.2K
Chicago Partners Investment Group LLC10,729$41.2K
Citadel Advisors LLC11,030$22.6K
Citigroup Inc74$152